Celldex Therapeutics (CLDX) Cash from Investing Activities Growth (1y) (2011 - 2026)
Celldex Therapeutics (CLDX) Cash from Investing Activities Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 90.55% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 91.53% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.90% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7,936.68% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 26.37% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -157.08% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -89.24% |
| 10 | Celldex Therapeutics | 3.29 Bn | 2.58 Bn | -2.57 Mn | -612.58% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -612.58% |
| Mar 31, 2026 | 67.91% |
| Dec 31, 2025 | 130.49% |
| Sep 30, 2025 | 27.41% |
| Jun 30, 2025 | 206.69% |
| Mar 31, 2025 | 113.63% |
| Dec 31, 2024 | 114.05% |
| Sep 30, 2024 | 310.08% |
| Jun 30, 2024 | -4,114.00% |
| Mar 31, 2024 | -699.61% |
| Dec 31, 2023 | -648.36% |
| Sep 30, 2023 | -49.51% |
| Jun 30, 2023 | -95.40% |
| Mar 31, 2023 | 406.45% |
| Dec 31, 2022 | 264.76% |
| Sep 30, 2022 | 110.17% |
| Jun 30, 2022 | 281.72% |
| Mar 31, 2022 | -76.13% |
| Dec 31, 2021 | -161.40% |
| Sep 30, 2021 | -433.54% |